BP蛋白通过肠道菌群改善白血病患者肌肉丢失的机理研究

白血病患者面临严重的蛋白质丢失和骨骼肌萎缩，持续性的蛋白质营养不良能降低患者对治疗药物的耐受度，影响其术后生存质量。申请人前期研究发现具有混合消化速率的动植物蛋白（BP蛋白，即“乳清蛋白+大豆蛋白”）在减缓肌肉丢失方面具有显著优势。然而在疾病状态下，BP蛋白对肌肉的影响以及其潜在调控机理尚不清楚。本项目拟通过建立临床队列，研究BP蛋白如何影响白血病患者肌肉状态，及其对患者术后适合度改善程度的影响。最新研究发现肠道菌群能够参与调控肌肉代谢相关因子，本团队预研究结果也提示BP蛋白参与调控肠道菌群组成模式。因此，本项目将从肠道菌群的角度探索BP蛋白调控患者肌肉状态的新机制。最终，将试图寻找能够实现术前肌肉风险预测的核心菌群种属，为后续患者术前精准营养改提供科学依据。

Leukemia patients with severe protein loss and skeletal muscle atrophy, persistent protein malnutrition not only reduce the tolerance of patients to treatment, but also affect the quality of life. The applicants have confirmed that soy-whey blended protein (BP protein) with mixed digestion rate has a unique advantage in preventing muscle loss. Our preliminary data indicated that BP protein can effectively improve muscle mass in leukemia patients. However, the mechanisms are still not clear. Recently, it has been found that intestinal flora can be involved in the regulation of many physiological metabolic activities of the host, such as muscle metabolism. Therefore, we speculated that the gut microbiota may be involved in the regulation of BP protein on muscle atrophy in patients. In this study, we tried to explore how the BP protein can regulate the muscle atrophy and fitness via intestinal flora-depended manner. At the same time, based on the intestinal flora information, the pre-transplantation risk prediction of muscle atrophy and related fitness will be established.